Daunorubicin
Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma
National Cancer Institute (NCI)Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide National Cancer Institute (NCI) | Phase 3 | B |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 3 | B |
THIOGUANINE ANHYDROUS National Cancer Institute (NCI) | Phase 3 | B |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | B |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | B |
View all 14 →
Same molecule, other indications
Daunorubicin is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →